DermatologyNews.net

Dermatology Xagena

Xagena Mappa
Medical Meeting
Cardiobase
Onco News

Search results for "Adalimumab"

CHMP, the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency ( EMEA ), has issued a positive opinion recommending approval of Adalimumab ( Humi ...


Two clinical trials of Humira ( Adalimumab ), REVEAL and CHAMPION, have demonstrated promising results in psoriasis. Psoriasis is a chronic autoimmune disease that speeds the growth cycle of skin ...


A post hoc analysis has examined the effects of Adalimumab ( Humira ) in patients with scalp and/or nail psoriasis from BELIEVE, a randomized, controlled, multicentre phase 3 safety and efficacy trial ...


Results from a phase 3 pivotal study demonstrating that Adalimumab ( Humira ) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa ( HS ), specifi ...


Psoriasis is a chronic inflammatory disease associated with increased risk of cardiovascular death. Several studies have shown a beneficial effect of anti-TNF-alpha therapy on the mechanisms associate ...


The incidence of non-infectious uveitis on a background of psoriasis is estimated to be 7-20%. The use of tumor necrosis factor-alpha ( TNF-alpha ) inhibitors as a treatment for refractory uveitis is ...


Findings of a phase 3 study of patients with moderate to severe psoriasis demonstrating that nearly half of adult patients treated with Adalimumab ( Humira ) has achieved at least a 75% improvement in ...